Novartis non-small cell lung cancer treatment granted orphan status
The FDA granted orphan designation to Novartis Pharmaceuticals’ treatment of non-small cell lung cancer with MET genomic tumor aberrations, according to a post to the agency’s website.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.